Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.

Next Previous
Trial Profile

A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 137173A (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Herpes zoster
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline Biologicals; GSK

    • Most Recent Events

    • 25 Dec 2021 Primary endpoint (Anti-pneumococcal antibody titers) has been met, as per results published in the Journal of Infection
    • 25 Dec 2021 Primary endpoint (Anti-gE antibody concentrations) has been met, as per results published in the Journal of Infection
    • 25 Dec 2021 Primary endpoint (Number of subjects with a vaccine response) has been met, as per results published in the Journal of Infection
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top